The novel aryl
phosphate derivative of bromo-methoxy
zidovudine (ZDV/AZT) (compound WHI-07, CAS 213982-96-8) was found to be a potent antileukemic agent against human
leukemia,
lymphoma, and
multiple myeloma cell lines in MTT and clonogenic assays with low micromolar IC50 values. In addition,
WHI-07 was
antimitotic, leading to cell fusion and developmental arrest in the Zebrafish model of rapid cell proliferation.
WHI-07 was cytotoxic to drug-sensitive (NALM-6, MOLT-3, HL-60, P388) and multi-drug resistant (MDR)
leukemia cell lines (HL-60/VCR, HL-60/ADR, P388/ ADR). Treatment of
leukemia cells with
WHI-07 showed rapid and dramatic depletion of all cellular
nucleoside diphosphate and
triphosphate (NDP/NTP) pools, which would contribute to the overall reduction of
nucleic acid synthesis and cell death.
WHI-07 was rapidly metabolized to alaninyl ZDV monophosphate (Ala-ZDV-MP), the levels of which inversely correlated with cytotoxic IC50 values of
WHI-07.
Glutathione was found to mediate the in vitro and in vivo detoxification pathway of
WHI-07 to 3'-azidothymidine-5'-p-bromophenylmethoxyalaninyl
phosphate and Ala-ZDV-MP, respectively. The proposed intracellular metabolic pathway for
WHI-07 involves a
thiol-mediated dehalogenation step followed by the
paraoxon-sensitive
carboxylesterase-mediated reaction leading to the formation of Ala-ZDV-MP as the major intracellular metabolite.